Oral tablets have much lower bioavailability (around 1%) due to digestion
A comprehensive review in Pharmacological Research confirms that skeletal muscle changes with GLP-1 treatment appear to be adaptive, aligning with what you would expect given the amount of weight lost (Pereira et al., 2025)
What is tirzepatide and how does it work for weight loss
The phase 2b ENLIVEN trial, a multicenter, randomized, double-blind, placebo-controlled study, included 222 patients with biopsy-confirmed NASH and F2-F3 fibrosis, assigned to receive pegozafermin at doses of 15 mg weekly, 30 mg weekly, 44 mg every 2 weeks, or placebo for 24 weeks
Reduces Intestinal Inflammation: Lowers inflammation in both the small and large intestines
Many patients continue treatment long-term because the metabolic and appetite benefits become part of their health management plan